DIStal Versus COnventional Radial Access for COMPLEX Large-bore Percutaneous Coronary Intervention
NCT ID: NCT05490238
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
708 participants
INTERVENTIONAL
2023-08-31
2027-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In a prospective, multicenter, observational study including 41 patients undergoing CTO PCI using a left DRA with a 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan), technical success was achieved in 90.3% of patients and procedural success was achieved in 78.1% of patients. No post-procedural DRA RAO were detected by clinical assessment and Doppler ultrasound examination, and no radial artery occlusions at the site of the forearm were found. Doppler ultrasound imaging of the DRA at one month was available in 67.6% of patients, with only one case (4.3%) of DRA RAO. This proof-of-concept study demonstrates that DRA using a 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan) for CTO PCI is feasible and associated with a high procedural success rate and low vascular access-site complication rates.
No randomized clinical trial to date has however compared the feasibility and safety of a 7F DRA versus 7F TRA for PCI of complex coronary lesions, such as chronic total occlusions (CTO), left main coronary artery disease, heavily calcified lesions, complex bifurcations, or other complex coronary lesions for whom the operator anticipates that a 7F guiding catheter is indicated.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The small size of the radial artery remains an important limitation for the use of large bore guiding catheters (\>6 F), restricting thereby the treatment of highly complex lesions through the transradial approach. The 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan) is a dedicated radial sheath with a thinner wall and hydrophilic coating. It combines an inner diameter compatible with any 7F guiding catheter and an outer diameter smaller than current 7F sheaths.
A prospective, multicenter, observational study including 60 patients demonstrates that a transradial access (TRA) using the 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan) for complex coronary interventions is feasible and associated with a high rate of procedural success and a low rate of vascular complications.
In the Complex Large-Bore Radial Percutaneous Coronary Intervention (COLOR) randomized trial, 388 patients with planned PCI for complex coronary lesions were randomly allocated to a 7F TRA or 7F transfemoral access (TFA). Conventional TRA was associated with a significant reduction in clinically relevant access- site bleeding or vascular complications without affecting procedural success when compared to TFA among patients undergoing complex PCI with a 7F large bore access.
The use of the distal radial artery has recently emerged as a promising alternative access route to further reduce the risk of radial artery occlusion (RAO) and has been endorsed by recent International Consensus documents. The feasibility of a distal radial access (DRA) for coronary angiography and/or PCI has been demonstrated in several observational clinical registries and small-sized randomized clinical trials. In the recent prospective, multicenter, open label, randomized, controlled DIStal vs Conventional RADIAL access (DISCO RADIAL) trial, DRA was associated with low and similar rates of RAO at discharge when compared to conventional TRA among patients undergoing coronary angiography and/or PCI. There is however limited evidence on the feasibility and safety of 7F DRA for PCI. The potential advantages of DRA when compared to TRA are contrasted by a slightly smaller size of the distal radial artery potentially impacting on device selection and procedural planning and by its less predictable course, due to the pronounced tortuosity and angulation of the vessel, leading to an overall higher number of puncture attempts, a longer time to achieve arterial access and a higher rate of access failure. These limitations may preclude the use of DRA for PCI of complex coronary lesions when a large bore guiding catheter is needed. There is however limited evidence on the feasibility and safety of 7F DRA for PCI.
In a prospective, multicenter, observational study including 41 patients undergoing CTO PCI using a left DRA with a 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan), technical success was achieved in 90.3% of patients and procedural success was achieved in 78.1% of patients. No post-procedural DRA RAO were detected by clinical assessment and Doppler ultrasound examination, and no radial artery occlusions at the site of the forearm were found. Doppler ultrasound imaging of the DRA at one month was available in 67.6% of patients, with only one case (4.3%) of DRA RAO. This proof-of-concept study demonstrates that DRA using a 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan) for CTO PCI is feasible and associated with a high procedural success rate and low vascular access-site complication rates.
No randomized clinical trial to date has however compared the feasibility and safety of a 7F DRA versus 7F TRA for PCI of complex coronary lesions, such as chronic total occlusions (CTO), left main coronary artery disease, heavily calcified lesions, complex bifurcations, or other complex coronary lesions for whom the operator anticipates that a 7F guiding catheter is indicated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Distal radial access
Distal radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)
Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Conventional radial access
Conventional radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)
Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients presenting with CCS or ACS, including unstable angina or NSTEMI.
* Patients planned for PCI of complex coronary lesions, such as CTO, left main coronary artery disease, heavily calcified lesions, complex bifurcations, or other complex coronary lesions in whom the operator anticipates that a 7F guiding catheter is indicated.
* Patients able to provide written informed consent.
Exclusion Criteria
* Patients with cardiogenic shock.
* Patients on chronic hemodialysis.
* Patients with contraindications to TRA, such as occlusive upper arm peripheral artery disease, or known anatomic variants prohibiting TRA on both sides.
* Patients with medical conditions that may cause non-compliance with the study protocol and/or may confound the data interpretation.
* Patients unable to provide written informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Bern
OTHER
IGLESIAS Juan Fernando
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
IGLESIAS Juan Fernando
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan F. Iglesias, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Geneva
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique St. Joseph Arlon - Groupe Vivalia
Arlon, , Belgium
CHU Saint-Pierre
Brussels, , Belgium
CHU de Charleroi
Charleroi, , Belgium
Hôpital de La Louvière - Site Jolimont
La Louvière, , Belgium
Agaplesion Bethesda Krankenhaus Bergedorf
Hamburg, , Germany
Patras University Hospital
Pátrai, , Greece
Humanitas Research Hospital
Milan, , Italy
Basel University Hospital
Basel, Basel, Switzerland
Geneva University Hospitals
Geneva, Canton of Geneva, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Karsten Schenke, MD
Role: primary
Maëlle Achard, RN
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Iglesias JF, Leibundgut G, Heg D, Gasparini GL, Tsigkas G, Ungureanu C, Colletti G, Degrauwe S, Xaplanteris P, Schenke K, Achim A, van Leeuwen MA, Muresan M, Saito S, Sgueglia GA, Aminian A. Distal versus conventional radial large-bore access for percutaneous coronary intervention of complex coronary lesions: Rationale and design of the DISCO COMPLEX randomized superiority trial. Am Heart J. 2026 Feb;292:107291. doi: 10.1016/j.ahj.2025.107291. Epub 2025 Oct 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-0729
Identifier Type: -
Identifier Source: org_study_id